In the following video, Motley Fool health-care analyst David Williamson looks at pharmaceutical company Corcept (NASDAQ:CORT) for being one of the top-performing health-care stocks in January. Although shares were ripped in half when the company failed to launch its Cushing's disease drug Korlym in 2012, while competitor Novartis (NYSE:NVS) did receive FDA approval for its drug in this space, Signifor, Corcept was able to rebound in January by up to 52%. David tells us why the amount of cash Corcept has on hand means the company has plenty of time to get things right next time.
- Feb 5, 2013 at 4:40PM
- Health Care
- Corcept Therapeutics Incorporated (CORT) Q1 2019 Earnings Call Transcript
- Here's Why Corcept Therapeutics Shares Rose 11.5% in February
- Corcept Therapeutics Incorporated (CORT) Q4 2018 Earnings Conference Call Transcript
- Here's Why Corcept Therapeutics Fell as Much as 13.7% Today
- Here's Why Corcept Therapeutics Stock Fell as Much as 18.5% Today